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Abstract: Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is one the major limiting 
factor for the successful outcome of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), with 
a reported mortality rate of up to 50%. VOD/SOS is thought to result from an endothelial damage and occurs with a 
highly variable incidence ranging from 8% to 14%. Management of patients with VOD/SOS is based on both prevention 
and treatment, which rely on non-pharmacological approaches, for instance the control of additional risk factors, and 
pharmacologic treatments. 
Herein we provide a review of the current understanding for the management of patients with VOD/SOS after allogeneic 
HSCT. 
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INTRODUCTION 
Bone marrow, peripheral blood stem cells and 
umbilical cord blood transplantation are medical 
procedures that are widely used to treat diseases once 
thought incurable. Nevertheless, the risk of transplant-
related complications represents a major drawback in 
the allogeneic hematopoietic stem cell transplantation 
(HSCT) setting. Veno-occlusive disease (VOD), also 
known as sinusoidal obstruction syndrome (SOS), is a 
potentially life-threatening complication of HSCT, 
occurring with a highly variable incidence, ranging from 
8% to 14%. 
Aim of present short review is to summarize the 
current understanding for the management of patients 
with VOD/SOS after allogeneic HSCT. 
PATHOPHYSIOLOGY 
VOD results from obliterative inflammation of the 
terminal hepatic venules in zone 3 of the hepatic 
acinus. VOD has been now renamed as SOS since 
damage to the sinusoidal endothelium is considered 
the primary event. 
The pathophysiology of VOD involves the activation 
of and damage of Sinusoidal endothelial cells due to 
regimen-related toxicity inducing the subsequent 
release of toxic cytokines such as TNF-a and IL1b, the 
expression of adhesion molecules (ICAM-1 and VCAM-  
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1) and release of heparanase eventually resulting in a 
further damage of the endothelium and gap formation 
which may facilitate the escape of red blood cells and 
leucocytes into the space of Disse leading to narrowing 
of the sinusoids. 
DIAGNOSIS AND GRADING OF SEVERITY 
The diagnosis of VOD/SOS is primarily based on 
clinical criteria, according to the Baltimore [1] and 
modified Seattle criteria [2]. The original definition of 
Seattle criteria has been modified including the bilirubin 
level and the percentage of weight gain (Table 1). 
Nevertheless, it has now been recognized the 
presence of VOD/SOS with delayed onset as well as a 
defined clinical entity with less stringent diagnostic 
criteria and where hyperbilirubinemia should no longer 
be mandatory. According to these observations the 
EBMT endorsed the revised diagnostic criteria for 
VOD/SOS [3] (Table 1). Taken as a whole, the 
classical triad of weight gain, hepatomegaly with right 
upper quadrant pain and elevated bilirubin may be 
variable present and may be incomplete or even 
delayed particularly in pediatric patients. Hence, the 
diagnosis of VOD, clinically based, still remains difficult 
in a consistent number of cases. Nevertheless, an 
accurate and prompt diagnosis of VOD/SOS is 
important for early initiation of appropriate therapy. In 
this respect the availability of imaging techniques, 
serological markers (i.e. PAI-1) and the use of hepatic 
biopsy may be considered as useful tools to further 
improve the diagnostic accuracy, in particular when the 
diagnosis is unclear. In fact, it is worth while recalling 
that several other conditions including GVHD, 
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infections and drug toxicity mimicking hepatic VOD 
should be excluded.  
The presence of multi-organ failure (MOF) is 
commonly used as a marker of severity of the disease, 
although several grading have been proposed [4-6]. 
Very recently, the new EBMT criteria for grading 
VOD/SOS severity have been published, based on 
bilirubin level and its rate of change, the value of 
transaminases, weight gain, renal function and the time 
elapsed from the first clinical symptoms [3]. 
RISK FACTORS 
Recognition of potential risk factors for VOD/SOS is 
a key point for early diagnosis and prompt therapeutic 
intervention. A large number of risk factors have been 
identified for the development of VOD/SOS (Table 2). 
Table 2: Risk Factors for VOD/SOS After HSCT 
Patient and disease-related risk factors 
Older age 
Performance score 
Metabolic Syndrome 
Genetic* 
Leukemia in advance disease 
Pediatric population with: 
Osteopetrosis 
Thalassemia 
Hemophagocytic lymphohistiocytosis 
Inborn errors of metabolism 
Immunodeficiencies 
Pre-transplant risk factors 
Previous parenteral nutrition 
Iron overload 
Hepatic dysfunction: cirrhosis, fibrosis, 
active viral hepatitis 
Transplant-related risk factors 
Type of HSCT: 
MUD 
Mismatched 
T-cell replete 
Allogeneic > autologous 
Conditioning regimen: 
oral busulphan 
12 Gy TBI 
MAC>RIC 
busulphan-endoxan 
GVHD prophylaxis:  
Sirolimus+CNI 
Second HSCT 
Previous/concomitant medications 
Progestogens 
Gentuzumab ozogamicin 
Inotuzumab ozogamicin 
Abdominal irradiation 
Abbreviations: MUD, matched unrelated donor; TBI, total body irradiation; 
MAC, myeloablative conditioning; RIC, reduced intensity conditioning; CNI, 
calcineurin inhibitors 
*GSTM1-null genotype, C282Y allele, MTHFR 677CC/1298CC haplotype 
MANAGEMENT OF VOD/SOS 
Measures for the optimal management of patients 
with VOD/SOS encompass multiple steps aiming to 
prevent the occurrence of the disease or to treat an 
Table. 1: Clinical Criteria for VOD/SOS 
EBMT Criteria (3) 
Classical VOD/SOS Late Onset VOD/SOS 
Modified SEATTLE Criteria (2) BALTIMORE Criteria (1) 
First 21 days after HSCT >21 days after HSCT ≥ 2 of the following criteria in the first 20 days after HSCT 
During the first 21 days after HSCT, 
bilirubin must be > 2 mg/dL plus ≥ two of 
the following: 
bilirubin must be > 2 mg/dL 
plus ≥ two of the following: 
Classical VOD/SOS occurring 
>21 day after HSCT 
 
Bilirubin > 2 mg/dL 
 
hepatomegaly 
Painful hepatomegaly Or histologically proven VOD/SOS 
Hepatomegaly or right upper 
quadrant pain ascites 
Weight gain >5% 
 
 
Ascites 
 
 
Or ≥ 2 of the following: 
- Bilirubin > 2 mg/dL 
- Painful hepatomegaly 
- Weight gain >5% 
- ascites 
And hemadynamical and /or 
US evidence of VOD/SOS 
 
 
 
Weight gain >2% from pre-HSCT 
weight 
 
 
 
 
 
Weight gain >5% from pre-HSCT weight 
Abbreviations: HSCT, hematopoietic stem cell transplantation; US, ultrasound 
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already established VOD/SOS (Figure 1). Prophylaxis 
tends to minimize any additional risk factors or 
administer medications which have been demonstrated 
to be useful in the prevention of VOD/SOS. The 
treatment of VOD/SOS is primarily based on supportive 
care and pharmacological treatment while only few 
reports have described the use of alternative therapies 
including transjugular intrahepatic portosystemic shunt 
(TIPS) or liver transplant.  
 
Figure 1: Management of VOD/SOS. 
PROPHYLAXIS OF VOD/SOS 
Preventive measures aiming to reduce the risk of 
VOD/SOS and the severity of the disease represent the 
first reasonable approach. Two options should be 
considered as the foremost preventive strategies. First, 
to minimize potential risk factors: unfortunately only few 
of these may be considered as reversible risk factors 
which may in turn be of clinical utility to be included as 
a prophylactic measure. The choice of preparative 
regimen and GVHD prophylaxis may be modified to 
mitigate the risk of VOD/SOS as well as iron overload 
may be reverted before the transplant and certainly, 
concomitant treatments with hepatotoxic drugs (i.e. 
progestogens) should be avoided whenever feasible. 
Second, a pharmacological approach may be 
considered particularly in patients at high risk of 
VOD/SOS. Table 3 reports a summary of the studies 
evaluating the principal drugs used to prevent 
VOD/SOS.  
Pentoxyfilline (PTX)  
Associated with ciprofloxacin and prednisone has 
been investigated for prophylaxis of VOD due to the 
anti-TNF activity of this combination [7]. In fact, high 
TNF-alpha levels have been detected in transplant-
associated microangiophaties including GVHD and 
VOD. However, the risk of VOD was not reduced with 
the administration of PTX while the combination was 
associated with a significant higher risk of bacteremia.  
Antithrombin III (AT III) 
Levels have been found low in patients with 
VOD/SOS. According to this observation Haussmann 
et al. designed a prospective study in pediatric patients 
where 91 patients were given pre-emptive AT III 
replacement in case of AT III activity below 70%; this 
group of patient was compared to an historical control 
group of 71 patients who did not receive any 
prophylactic treatment [8]. The incidence of VOD/SOS 
was not significantly different between the two groups, 
however it should be emphasized that all 14 patients in 
the study group who developed VOD/SOS, showed 
subnormal AT III levels 1 day prior to the diagnosis of 
VOD/SOS.  
Heparin 
 Both unfractionated heparin (UFH) and low 
molecular weight heparin (LMWH) have been 
investigated as preventive strategies to decrease the 
risk of VOD/SOS, but only three studies are 
prospective and randomized [9-11]. The studies of Attal 
and Marsa-Vila included UFH (Table 3), while LMWH 
has been evaluated by Or et al including 61 patients 
receiving allogeneic and autologous HSCT who were 
randomized to receive LMWH or placebo. Patients who 
were given LMWH had a reduced incidence of 
hepatomegaly and a reduced duration of elevated 
bilirubin (p 0.04 and p 0.01, respectively). A recent 
meta-analysis addressing the role of heparin as 
prevention of VOD/SOS identified 12 studies including 
2782 HSCT recipients. The study showed a statistically 
non-significant beneficial effect of heparin, however the 
diversity of the studies might have precluded 
meaningful conclusions as witnessed by the extreme 
wide range of VOD/SOS incidence spanning from 2% 
up to 82% [12]. 
Prostaglandin E1 (PGE1) 
The most recent study compared retrospectively the 
efficacy of PGE1 in a group of 40 patients with 10 
patients who received heparin and 35 patients who did 
not receive any prophylaxis. No patients in the PGE1 
and heparin group developed VOD as compared to an 
incidence of 14% of VOD/SOS in patients not receiving 
any drug [13].  
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Ursodeoxycholic Acid (UDCA) 
Three prospective randomized trials addressed the 
role of UDCA for the prevention of VOD/SOS (Table 3). 
A systematic review of the studies on the use of UDCA 
for the prevention of VOD/SOS has been published 
[14]. Overall, 6 studies including 824 patients have 
been analyzed. The review demonstrated that 
Table 3: Summary of Pharmacological Measures for Prevention of VOD/SOS 
 Study group (No. Patients) 
Control group 
(No. Patients) P value 
Ferra’, 1997 [7] PTX-CIPRO-PDN No. 37 No. 16  
VOD 8% 25% 0.19 
Bacteremia 62% 17% 0.05 
Mucositis 3-4 grade 32% 56% NS 
GVHD III-IV 28% 14% NS 
Haussmann, 2006 [8] AT III - No. 91 No. 71  
VOD 15% 18% NS 
Marsa-Vila, 1991 [11] UFH – No. 52 No. 46  
VOD 7.7% 2.2% NS 
Attal, 1992 [9] UFH – N0.81 No. 80  
VOD 2.5% 13.7% 0.01 
Song, 2006 [13] PGE1 - No. 40 Heparin  No. 10 
No prophylaxis 
No. 35  
VOD 0% 0% 14% 0.02 
Ohashi, 2000 [31] UDCA – No. 67  No. 65  
VOD 3% 18.5% 0.004 
Ruutu, 2002 [32] UDCA – No. 123  No. 119  
VOD, Jones criteria 
McDonald criteria 
2% 
11% 
4% 
12% 
NS 
NS 
GVHD III-IV 4% 14% 0.01 
Chronic GVHD 47% 45% NS 
NRM at 1 year 19% 34% 0.01 
Park, 2002 [33] 
UDCA+Heparin 
No. 82 
Heparin 
No. 83 
 
VOD 15.9% 19.3% 0.348 
Median day of VOD onset 11 12 0.9 
VOD after Allogeneic HSCT 34% 30% 0.702 
Corbacioglu, Lancet 2012 [19] DFT - No. 180 No. 176  
VOD by d30 12% 20% 0.04 
Median time to diagnosis, days 17.5 14 0.5 
VOD by donor type 
Allogeneic 
autologous 
 
8% 
4% 
 
14% 
6% 
 
- 
hemorrhage 22% 21% 0.8 
TAM 3% 4% 0.75 
GVHD II-IV 22% 37% 0.013 
Abbreviations. PTX, Pentoxifylline; CIPRO, Ciprofloxacine; PDN, prednisone; AT III, antithrombin III; LMWH; low molecolar weight heparin; PGE1, Prostaglandin 
E1; UDCA, Ursodeoxycholic acid; NMR, nonrelapse mortality; DFT, Defibrotide; TAM, thrombotic microangiopathy.  
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prophylaxis with UDCA significantly attenuates the risk 
of VOD/SOS resulting in a lower TRM and a trend 
toward a lower rate of acute GVHD.  
Defibrotide (DFT) 
Is a mixture of oligonucleotides derived from 
depolymerization of cow lung or porcine intestinal 
mucosa. DFT was primarily investigated as an ade- 
nosine receptor agonist and only subsequent studies 
have shown its antithrombotic properties. Table 4 
summarizes the main activities of DFT.  
Table 4: Main Activities of Defibrotide (DFT) 
(1) VASCULAR 
INTEGRITY 
 
- Reduces vascular permeability 
- Reduces vascular inflammation 
- Promote angiogenesis 
(2) ANTITHROMBOTIC 
and THROMBOLITIC 
properties 
- Increasing levels of tPA 
- Increasing activity of plasmin 
- Reducing PAI-1 levels 
- Reducing platelet activating factor 
- Reducing thrombin 
(3) ANTI-
INFLAMMATORY 
effects 
- Increases PGE2 and prostacyclin 2 
- Reduces:   IL-6 
               thromboxane A2 
            leukotriene B4 
                        TNF 
 ICAM-1 
(4) Protective effect 
against GVHD 
- Inhibits T-cell function (through 
activation of adenosine receptor) and 
proliferation 
- decreases TNF, IL-1, IL-2 
 
Several studies have evaluated the efficacy and 
toxicity profile of DFT for prophylaxis of VOD/SOS in 
both adult and pediatric patients [15-18]. A phase 3 
open-label prospective trial including 356 children who 
received autologous (n=108) or allogeneic (n=248) 
HSCT has been recently published [19]. Overall, 180 
patients were allocated in the DFT group and 176 in 
the control group. DFT was administered at the dose of 
25 mg/Kg/day from day 0 until day +30. Patients had 
one or more risk factors for VOD/SOS: (i) pre-existing 
liver disease, (ii) second myeloablative HSCT, (iii) 
leukemia in > 2nd relapse, (iiii) preparative regimen 
including busulphan and melphalan, (iiiii) previous 
treatment with gemtuzumab ozogamicin and (iiiiii) 
diagnosis of lymphohistiocytosis, adrenoleuko- 
dystrophy or osteopetrosis. The results of the study 
demonstrated that 12% of the patients who received 
DFT developed VOD/SOS by day 30 post-HSCT, 
compared to 20% of the patients in the control group  
(p 0.04). Interestingly, in allogeneic HSCT recipients, 
the incidence and severity of acute GVHD were lower 
in the DFT group as compared to the control group  
(Table 3).  
Guidelines 
In accordance to the findings of the Corbacioglu’s 
study, the British guidelines recommend prophylaxis 
with DFT 6.25 mg/kg QID both in children (1A) and 
adults (2B) receiving allogeneic HSCT with the 
abovementioned six risk factors [20]. UDCA may 
considered as an alternative drug with a lower strength 
of recommendation (2C). PGE1, PTX and ATIII are not 
recommended due to lack of efficacy, while UFH and 
LMWH are not recommended due to the risk of 
bleeding. Similar recommendations have been 
proposed by the EBMT Group [21]. 
SUPPORTIVE CARE 
An adequate supportive care may represent the first 
measure for VOD/SOS treatment even when the 
diagnosis is only suspected. The maintenance of a 
correct fluid balance along with the administration of 
diuretics for severe fluid overload re of extreme 
importance. Paracentesis should be considered to 
symptomatically improve the discomfort caused by 
ascites and to avoid a reduction in renal flow. 
Hemodyalisis/hemofiltration should be considered in 
case of uncontrolled fluid retention and renal failure. It 
is noteworthy recalling the importance of an early 
discussion with a specialist hepatology unit in order to 
evaluate alternative options for instance TIPS and liver 
transplantation.  
PHARMACOLOGICAL TREATMENT OF VOD/SOS 
Recombinant Human Tissue Plasminogen Activator 
(rh-TPA) 
The largest retrospective study analyzed 42 patients 
with VOD/SOS who were treated with rh-TPA and 
heparin [22]. Patients received rh-TPA at a dose 
ranging from 5.4 to 120 mg i.v. over 2-4 days in 
association with heparin (1000 U as bolus dose 
followed by 150 U/Kg/day by continuous infusion for 10 
days). Complete remission of VOD/SOS and day +100 
overall survival (OS) have been reported in 29% and 
24% of the patients respectively; severe bleeding 
episodes have been observed in 10 patients.  
N-Acetylcysteine (NAC) 
NAC is an antioxidant glutathione precursor that 
may reduce cell death mediated by oxidative stress. 
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NAC is commonly used as an antidote for the overdose 
of paracetamol hepatotoxicity and may provide 
protection from liver toxicity. One prospective 
randomized trial investigated the usefulness of NAC in 
allogeneic HSCT recipients [23]. Patients with bilirubin 
> 26 mmol/L and/or AST/ALT > 84 U/L were 
randomized to receive NAC 100 mg/Kg/day i.v. (n=72) 
or no treatment (n=88). Maximum bilirubin level and 
recovery of AST/ALT were similar in patients 
randomized to NAC or no treatment. The authors 
conclude that NAC does not improve liver toxicity in 
patients undergoing HSCT. 
Methylpredisolone (MP) 
One prospective study evaluated the safety and 
efficacy of MP in 48 patients with diagnosis of 
VOD/SOS. MP was administered at the dose of 0.5 
mg/Kg BID for 14 days [24]. Response rate was 63%, 
however relevant treatment-related toxicities have been 
reported: 17% of the patients developed sepsis, 34% of 
the patients developed CMV infection and 10% of the 
patients presented with invasive fungal infections. 
Defibrotide (DFT) 
Table 5 reports a summary of the studies regarding 
the treatment of VOD/SOS with DFT.  
The results of a phase 3 study investigating safety 
and efficacy of DFT in patients with VOD/SOS and 
multi-organ failure (MOF) have been recently published 
[25]. Overall 102 patients given DFT 25 mg/Kg/day 
were compared to 32 historical controls. Complete 
remission by day +100 was 25.5% and 12.5% 
respectively in the DFT and control group (p 0.0160), 
and OS by day +100 was 38% vs. 25% in the two 
groups (p 0.0109). Main treatment-related adverse 
events in the DFT group and control group included 
hypotension (respectively 39% vs. 50%), hematuria 
(respectively 10% and 16%), pulmonary alveolar 
hemorrhage (respectively 12% and 16%) and gastro-
intestinal bleeding (respectively 8% and 9%).  
One of the largest retrospective studies included 
8341 patients selected from the Center for International 
Blood and Marrow Transplant Research (CIBMTR) 
Table 5: Summary of the Studies Regarding Treatment of VOS/SOS with Defibrotide (DFT) 
Reference Population Study Treatment Option & Sample Size 
Complete 
Remission (%) 
Outcome 
(d+100 OS) 
Toxicity 
(Tretment-Relted AEs) 
Sucak, 2007 [34] Adult Retrospective DFT 10-25 mg/Kg/d, n=14 78% 78% - 
DFT 25 mg/Kg, n=75 46%  44%  7%   
Richardson, 
2010 [28] 
 
 
Adult & children 
Prospective 
 
Randomized DFT 40 mg/Kg, n=74 42% 39% 10% 
Corbacioglu, 
2004 [35] Children Retrospective DFT 40 mg/Kg, n=45 76% 64% 7% discontinution 
Triplett,  
2015 [27] Adult & children Prospective 
Dose finding 10 mg/kg up 
to 110 mg/Kg (n=34) 56% 44% Bleeding, hypotension 
Corbacioglu, 
2016 [36] Adult & children Retrospective 
DFT 10-25-40-60-80 
mg/Kg/d, n=710 - 54% - 
 
Richardson, 
2016 [37] 
Adult & children 
 
Acute Leukemia. 
 
 
Retrospective 
 
 
DFT 25 mg/Kg/d, n=756 
 
 
- 
AML 45% 
 
ALL 43% 
AML 22% 
 
ALL 17% 
DFT 25 mg/Kg/d, n=102 25%  38%  
Hypotension: 39% 
GI bleeding: 8% 
 
 
Richardson, 
2016 [25)] 
 
 
Adult & children 
 
 
Phase III study 
Historical controls,n=32 12% 25% Hypotension: 50% GI bleeding: 9% 
Strouse,  
2016 [26] Adult & children Retrospective DFT vs Other treatments 51% vs 29% 
39% vs 
30% - 
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database [26]. VOD/SOS and severe VOD/SOS 
defined as disease occurring in the setting of multi-
organ failure, were identified in 3.2% and 1.2% of the 
patients respectively. Among patients with severe 
VOD/SOS, 41 were treated with DFT and 55 did not 
receive DFT. Patients in the DTF group were older, 
were more likely to have previous fungal infection and 
had higher proportion of organ impairment. Complete 
response of VOD/SOS at day+100 was 51% in the 
DFT group and 29% in the control group, while OS at 
day +100 was 39% and 30% in the two groups 
respectively. Interestingly, the incidence of grade II-IV 
and III-IV acute GVHD were 23% and 11% in the DFT 
group as compared to 38% and 29% in the control 
group. This finding combined with the data of 
Corbacioglu et al. [19] showing a lower incidence and 
severity of GVHD among patients who received DFT as 
prophylaxis for VOD/SOS, further strengthen the 
observation of a potential protective effect of DFT on 
GVHD, in accordance to the immunomodulatory effects 
of DFT which includes the inhibition of T-cell activity 
and proliferation, and reduction of TNF, IL-1, IL-2 levels 
(Table 4).  
The optimal dosage of DFT has been investigated 
in several studies. Triplett et al conducted a 
prospective trial evaluating escalating dosed of DFT 
from 10 mg/Kg up to 110 mg/Kg/day [27]. The dose of 
DFT could be safely escalated up to 100 mg/Kg/day 
without an increase in bleeding risk, however the 
efficacy of DFT at higher doses remains unclear. 
Richardson et al. published a randomized phase II 
dose-finding trial assessing the efficacy of DFT in 
allogeneic HSCT recipients with severe VOD/SOS [28]. 
Adult and pediatric patients were randomized to 
receive DFT at the dose of 25 mg/Kg/day (DFT25 
group, n=75) or 40 mg/Kg/day (DFT40 group, n= 74). 
Overall, complete response was reported in 49% of the 
DFT25 patients and 43% of the DF40 patients (p 
0.613), and the rates of complete responses were not 
significant different in a subgroup analysis of adult and 
pediatric patients. Similarly, OS at day +100 was not 
different in the DFT25 and DFT40 group, and 
treatment-related adverse events have been reported 
in 7% of the patients in the DFT25 group and 10% of 
the patients in the DFT40 group (p 0.563). In 
conclusion, DFT at the dose of 25 mg/Kg/dy 
demonstrated to be effective in treating severe 
VOD/SOS as the dose of 40 mg/Kg/day with low 
treatment-related toxicity. 
The optimal time to initiate the treatment of 
VOD/SOS with DFT represents a critical issue. Several 
studies suggest the earlier intervention may be 
associated with a more favorable outcome [29]. Sixty % 
of patients were alive when defibrotide was started 
within 2 days from the onset of symptoms as compared 
with 14% when treatment was delayed and started 
after 7 days [30].  
Guidelines 
The British guidelines recommend the use of DFT 
for the treatment of adults and pediatric patients with 
VOD/SOS (1B) [20]. By contrast, rh-TPA and NAC are 
not routinely recommended, due to the risk of 
hemorrhage (rh-TPA) and lack of efficacy (NAC). MP 
may be considered with caution due to the risk of 
severe infections.  
CONCLUSION  
The management of VOD/SOS must initiate with 
timely diagnosis of the disease, including the 
recognition of early signs and symptoms and the use of 
serological markers, imaging and even invasive 
procedures when the diagnosis in unclear and requires 
the exclusion of other confounding conditions (i.e. 
GVHD, infections, drug toxicity). Preventive measures 
include the recognition of risk factors which might be 
reverted and pharmacological interventions, for 
instance the administration of UDCA and DFT in high 
risk patients. The treatment of an overt VOD/SOS 
includes an adequate supportive care and the 
administration of drugs with proven efficacy such as 
DFT. It should be emphasized that the treatment of 
VOD/SOS with DFT is associated with better outcome 
particularly when DFT is administered within the first 2 
days from the diagnosis. 
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